Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene

Cellular Oncology

Volumn 31, Issue 5, 2009, Pages 371-382

  Baldewijns, Marcella M ^a,e   Van Vlodrop, Iris J H ^a   Smits, Kim M ^a   Vermeiden, Peter B ^b   Van Den Eynden, Gert G ^b   Schot, Fiona ^a   Roskams, Tania ^c   Van Poppel, Hein ^b   Van Engeland, Manon ^a,d   De Bruïne, Adriaan P ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c General Hospital   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis; Renal cell carcinoma; VHL

Indexed keywords

ANGIOGENIC FACTOR; VON HIPPEL LINDAU PROTEIN;

AGED; ANGIOGENESIS; ARTICLE; CLEAR CELL CARCINOMA; CPG ISLAND; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN METHYLATION;

AGED; ANOXIA; CARCINOMA, RENAL CELL; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MUTATION; PROMOTER REGIONS, GENETIC; TREATMENT OUTCOME; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 70149092348     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/704212     Document Type: Article

References (56)

1. [1] W.Y. Kim and W.G. Kaelin, Role of VHL gene mutation in human cancer, J. Clin. Oncol. 22 (2004), 4991-5004. (Pubitemid 46646218)
2. E.R. Maher, Von Hippel-Lindau disease, Curr: Mol. Med. 4 (2004), 833-842.
3. [3] J.R. Gnarra, K. Tory, Y. Weng, L. Schmidt, M.H. Wei, H. Li, F. Latif, S. Liu, F. Chen, F.M. Duh et al., Mutations of the VHL tumour suppressor gene in renal carcinoma, Nat. Genet. 7 (1994), 85-90. (Pubitemid 24232386)
4. [4] B. Zbar, T. Kishida, F. Chen, L. Schmidt, E.R. Maher, F.M. Richards, P.A. Crossey, A.R. Webster, N.A. Afiara, M.A. Ferguson-Smith, H. Brauch, D. Glavac, H.P. Neumann, S. Tisherman, J.J. Mulvihill, D.J. Gross, T. Shuin, J. Whaley, B. Scizing, N. Kley, S. Olschwang, C. Boisson, S. Richard, C.H. Lips, M. Lerman et al., Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan, Hum. Mutat. 8 (1996), 348-357. (Pubitemid 26412151)
5. R.E. Banks, P. Timkonda, C. Taylor, N. Hornigold, D. Astuti, D. Cohen, E.R. Maher, A.J. Stanley, P. Harnden, A. Joyce, M. Knowles and P.J. Selby, Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer, Cancer Res. 66 (2006), 2000-2011.
6. [6] E. Dulaimi, I. Ibanez de Caceres, R.G. Uzzo, T. Al-Saleem, R.E. Greenberg, T.J. Polascik, J.S. Babb, W.E. Grizzle and P. Cairns, Promoter hypermethylation profile of kidney cancer, Clin. Cancer Res. 10 (2004), 3972-3979. (Pubitemid 38812470)
7. [7] C. Battagli, R.G. Uzzo, E. Dulaimi, I. Ibanez de Caceres, R. Krassenstein, T. Al-Saleem, R.E. Greenberg and P. Cairns, Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients, Cancer Res. 63 (2003), 8695-8699. (Pubitemid 38064046)
8. [8] J.G. Herman, F. Latif, Y. Weng, M.I. Lerman, B. Zbar, S. Liu, D. Samid, D.S. Duan, J.R. Gnarra, W.M. Linehan et al., Silencing of the VHL tumor-suppressor gene by DNA methylation in. renal carcinoma, Proc. Natl. Acad. Sci. USA 91 (1994), 9700-9704. (Pubitemid 24311875)
9. M. Ohh, C.W. Park, M. Ivan, M.A. Hoffman, T.Y. Kim, L.E. Huang, N. Pavletich, V. Chau and W.G. Kaelin, Ubiquitination of hypoxia-inducible factor requires direct binding to the betadomain of the von Hippel-Lindau protein, Nat. Cell. Biol. 2 (2000), 423-427.
10. K. Tanimoto, Y. Makino, T. Pereira and L. Poellinger, Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein, EMBO J. 19 (2000), 4298-4309.
11. [11] L.E. Huang, J. Gu, M. Schau and H.F. Bunn, Regulation of hypoxia-inducible factor 1 alpha is mediated by an 02dependent degradation domain via the ubiquitin-proteasome pathway, Proc. Natl. Acad. Sci. USA 95 (1998), 7987-7992. (Pubitemid 28326053)
12. [12] K. Kondo and W.G. Kaelin, Jr., The von Hippel-Lindau tumor suppressor gene, Exp. Cell Res. 264 (2001), 117-125. (Pubitemid 32989086)
13. [13] P. Carmeliet, Y. Dor, J.M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwell, C.J. Koch, P. Ratcliffe, L. Moons, R.K. Jain, D. Collen and E. Keshert, Role of HIF-lalpha in hypoxiamediated apoptosis, cell proliferation and tumour angiogenesis, Nature 394 (1998), 485-490. (Pubitemid 28373960)
14. M.S. Wiesener, P.M. Munchenhagen, I. Berger, N.V. Morgan, J. Roigas, A. Schwiertz, J.S. Jurgensen, G. Gruber, P.H. Maxwell, S.A. Loning, U. Frei, E.R. Maher, H.J. Grone and K.U. Eckardt, Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor1alpha in clear cell renal carcinomas, Cancer Res. 61 (2001), 5215-5222.
15. J.R. Gnarra, S. Zhou, M.J. Merrill, J.R. Wagner, A. Krumm, E. Papavassiliou, E.H. Oldfield, R.D. Klausner and W.M. Linehan, Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene, Proc. Natl. Acad. Sci. USA 93 (1996), 10589-10594.
16. M.M. Baldewijns, V.L. Thijssen, G.G. Van den Eynden, S.J. Van Laere, A.M. Bluekens, T. Roskams, H. van Poppel, A.P. De Bruine, A.W. Griffioen and P.B. Vermeulen, High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile, Br: J. Cancer 96(2007), 1888-1895.
17. W.G. Kaelin, Jr., The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma, Clin. Cancer Res. 13 (2007), 680s-684s.
18. J.G. Herman, J.R. Graff, S. Myohanen, B.D. Nelkin and S.B. Baylin, Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands, Proc. Natl. Acad. Sci. USA 93 (1996), 9821-9826.
19. M. van Engeland, M.P. Weijenberg, G.M. Roemen, M. Brink, A.P. de Bruine, R.A. Goldbohm, P.A. van den Brandt, S.B. Baylin, A.F. de Goeij and J.G. Herman, Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: The Netherlands cohort study on diet and cancer, Cancer Res. 63 (2003), 3133-3137.
20. [20] G.G. Van den Eynden, I. Van der Auwera, S.J. Van Laere, C.G. Colpaert, H. Turley, A.L. Harris, P. van Dam, L.Y. Dirix, P.B. Vermeulen and E.A. Van Marck, Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer, Br. J. Cancer 93 (2005), 1128-1136. (Pubitemid 41670697)
21. K. Foster, A. Prowse, A. van den Berg, S. Fleming, M.M. Hulsbeek, P.A. Crossey, F.M. Richards, P. Cairns, N.A. Affara, M.A. Ferguson-Smith and et al., Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma, Hum. Mol. Genet. 3 (1994), 2169-2173.
22. P. Schraml, K. Struckmann, F. Hatz, S. Sonnet, C. Kully, T. Gasser, G. Sauter, M.J. Mihatsch and H. Moch, VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma, J. Pathol. 196 (2002), 186-193.
23. K. Kondo, M. Yao, M. Yoshida, T. Kishida, T. Shuin, T. Miura, M. Moriyama, K. Kobayashi, N. Sakai, S. Kaneko, S. Kawakami, M. Baba, N. Nakaigawa, Y. Nagashima, Y. Nakatani and M. Hosaka, Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters, Genes Chmmosomes Cancer 34 (2002), 58-68.
24. [24] K. Hamano, M. Esumi, H. Igarashi, K. Chino, J. Mochida, I. A. H. and K. Okada, Biallelic inactivation of the von HippelLindau tumor suppressor gene in sporadic renal cell carcinoma, J. Urol. 167(2002), 713-717. (Pubitemid 34074572)
25. K.P. van Houwelingen, B.A. van Dijk, C.A. Hulsbergen-van de Kaa, L.J. Schouten, H. J. Gorissen, J.A. Schalken, P.A. van den Brandt and E. Oosterwijk, Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study, BMC Cancer 5 (2005), 57.
26. [26] K. Grabmaier, M.C.A. de Weijert, G.W. Verhaegh, J.A. Schalken and E. Oosterwijk, Strict regulation of CAIX(G250/MN) by HIF-lalpha in clear cell renal cell carcinoma, Oncogene 23 (2004), 5624-5631. (Pubitemid 39093040)
27. G.L. Semenza, Targeting HIF-1 for cancer therapy, Nat. Rev. Cancer 3 (2003), 721-732.
28. S. Kaluz, M. Kaluzova and E.J. Stanbridge, Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxiaresponsive enhancer, Cancer Res. 63 (2003), 917-922.
29. K.M. Smits, L.J. Schouten, B.A. van Dijk, C.A. Hulsbergenvan de Kaa, K.A. Wouters, E. Oosterwijk, M. van Engeland and P.A. van den Brandt, Genetic and epigenetic alterations in the von Hippel-Lindau gene: the influence on renal cancer prognosis, Clin. Cancer Res. 14 (2008), 782-787.
30. [30] A. Lidgren, Y. Hedberg, K. Grankvist, T. Rasmuson, A. Bergh and B. Ljungberg, Hypoxia-inducible factor 1 alpha expression in renal cell carcinoma analyzed by tissue microarray, Eur. Urol. 50 (2006), 1272-1277. (Pubitemid 44692925)
31. A. Lidgren, Y. Hedberg, K. Grankvist, T. Rasmuson, J. Vasko and B. Ljungberg, The expression of hypoxia-inducible factor 1 alpha is a favorable independent prognostic factor in renal cell carcinoma, Clin. Cancer Res. 11 (2005), 1129-1135.
32. T. Klatte, D.B. Seligson, S.B. Riggs, J.T. Leppert, M.K. Berkman, M.D. Kleid, H. Yu, F.F. Kabbinavar, A.J. Pantuck and A.S. Belldegrun, Hypoxia-inducible factor 1 (alpha) in clear cell renal cell carcinoma, Clin. Cancer Res. 13 (2007), 7388-7393.
33. J.P. Ioannidis, Why most published research findings are false, PLoS Med. 2 (2005), el24.
34. J.P. Ioannidis, Molecular bias, Eur: J. Epidemiol. 20 (2005), 739-745.
35. J.P. Ioannidis, Is molecular profiling ready for use in clinical decision making?, Oncologist 12 (2007), 301-311.
36. I.A. Lubensky, J.R. Gnarra, P. Bertheau, M.M. Walther, W.M. Linehan and Z. Zhuang, Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients, Am. J. Pathol. 149 (1996), 2089-2094.
37. [37] A.H. Prowse, A.R. Webster, F.M. Richards, S. Richard, S. Olschwang, F. Resche, N.A. Affara and E.R. Maher, Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors, Am. J. Hum. Genet. 60 (1997), 765-771. (Pubitemid 27146484)
38. N. Hay, The Akt-mTOR tango and its relevance to cancer, Cancer Cell 8 (2005), 179-183.
39. C. Blancher, J.W. Moore, N. Robertson and AL. Harris, Effects of ras and von Hippel-Lindau (VHL) gene mutations on. hypoxia-inducible factor (HIF)-Ialpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway, Cancer Res. 61 (2001), 7349-7355.
40. H. Oka, Y. Chatani, R. Hoshino, O. Ogawa, Y. Kakehi, T. Terachi, Y. Okada, M. Kawaichi, M. Kolmo and O. Yoshida, Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma, Cancer Res. 55 (1995), 4182-4187.
41. D. Huang, Y. Ding, W.M. Luo, S. Bender, C.N. Qian, E. Kort, Z.F. Zhang, K. VandenBeldt, N.S. Duesbery, J.H. Resau and B.T. Teh, Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo, Cancer Res. 68 (2008), 81-88.
42. D.A. Walsh, Pathophysiological mechanisms of angiogenesis, Adv. Clin. Chem. 44 (2007), 187-221.
43. C.C. Wykoff, C.W. Pugh, PH. Maxwell, A.L. Harris and P.J. Ratcliffe, Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling, Oncogene 19 (2000), 6297-6305.
44. [44] R.R. Raval, K.W. Lau, M.G. Tran, H.M. Sowter, S.J. Mandriota, J.L. Li, C.W. Pugh, P.H. Maxwell, A.L. Harris and P.J. Ratcliffe, Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma, Mol. Cell. Biol. 25 (2005), 5675-5686. (Pubitemid 40853601)
45. Y. Mizukami, Y. Kohgo and D.C. Chung, Hypoxia inducible factor-1 independent pathways in tumor angiogenesis, Clin. Cancer Res. 13 (2007), 5670-5674.
46. [46] Y. Jiang, W. Zhang, K. Kondo, J.M. Klco, TB. St Martin, M.R. Dufault, S.L. Madden, W.G. Kaelin, Jr. and M. Nacht, Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways, Mol. Cancer Res. 1 (2003), 453-462. (Pubitemid 36459256)
47. X. Na, G. Wu, C.K. Ryan, S.R. Schoen, P.A. di'Santagnese and E.M. Messing, Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas, J. Urol. 170 (2003), 588-592.
48. K.J. Turner, J.W. Moore, A. Jones, C.F. Taylor, D. CuthbertHeavens, C. Han, R.D. Leek, K.C. Gatter, P.H. Maxwell, P.J. Ratcliffe, D. Cranston and A.L. Harris, Expression of hypoxiainducible factors in. human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation, Cancer Res. 62 (2002), 2957-2961.
49. T. Shinojima, M. Oya, A. Takayanagi, R. Mizuno, N. Shimizu and M. Murai, Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth, factor expression through. HIF-2alpha, Carcinogenesis 28 (2007), 529-536.
50. [50] R.H. Weiss and P.Y. Lin, Kidney cancer: identification of novel targets for therapy, Kidney Int. 69 (2006), 224-232. (Pubitemid 43323071)
51. B. Zbar, R. Klausner and W.M. Linehan, Studying cancer families to identify kidney cancer genes, Annu. Rev. Med. 54 (2003), 217-233.
52. C. Morrissey, A. Martinez, M. Zatyka, A. Agathanggelou, S. Honorio, D. Astuti, N.V. Morgan, H. Moch, F.M. Richards, T. Kishida, M. Yao, P. Schraml, F. Latif and E.R. Maher, Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma, Cancer-Res. 61 (2001), 7277-7281.
53. A. van den. Berg, M.F. Hulsbeek, D. de Jong, K. Kok, P.M. Veldhuis, J. Roche and C.H. Buys, Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis, Genes Chromosomes Cancer 15 (1996), 64-72.
54. CA. Thrash-Bingham, H. Salazar, J.J. Freed, R.E. Greenberg and K.D. Tartof, Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology, Cancer Res. 55 (1995), 6189-6195.
55. [55] H. Moch, J.C Presti, Jr., G. Sauter, N. Buchholz, P. Jordan, M.J. Mihatsch and F.M. Waldman, Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma, Cancer Res. 56 (1996), 27-30. (Pubitemid 26010380)
56. H. Brauch, S. Pomer, T. Hieronymus, T. Schadt, H. Lohrke and D. Komitowski, Genetic alterations in sporadic renal-cell carcinoma: molecular analyses of tumor suppressor gene harboring chromosomal regions 3p, 5q, and 17p, World J. Urol. 12 (1994), 162-168.